Finding a peripheral biomarker for early Alzheimer disease (AD) is a major challenge. A recent study has validated a plasma protein signature that is associated with mild cognitive impairment and AD, and could predict conversion; however, longitudinal cohort studies of presymptomatic individuals are needed to confirm the findings.
